232 related articles for article (PubMed ID: 24501405)
1. Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity.
Schotte L; Strauss M; Thys B; Halewyck H; Filman DJ; Bostina M; Hogle JM; Rombaut B
J Virol; 2014 Apr; 88(8):4403-13. PubMed ID: 24501405
[TBL] [Abstract][Full Text] [Related]
2. Five of Five VHHs Neutralizing Poliovirus Bind the Receptor-Binding Site.
Strauss M; Schotte L; Thys B; Filman DJ; Hogle JM
J Virol; 2016 Jan; 90(7):3496-505. PubMed ID: 26764003
[TBL] [Abstract][Full Text] [Related]
3. Cryo-electron Microscopy Structures of Expanded Poliovirus with VHHs Sample the Conformational Repertoire of the Expanded State.
Strauss M; Schotte L; Karunatilaka KS; Filman DJ; Hogle JM
J Virol; 2017 Feb; 91(3):. PubMed ID: 27852863
[TBL] [Abstract][Full Text] [Related]
4. In vitro antiviral activity of single domain antibody fragments against poliovirus.
Thys B; Schotte L; Muyldermans S; Wernery U; Hassanzadeh-Ghassabeh G; Rombaut B
Antiviral Res; 2010 Aug; 87(2):257-64. PubMed ID: 20566349
[TBL] [Abstract][Full Text] [Related]
5. Antipoliovirus activity and mechanism of action of 3-methylthio-5-phenyl-4-isothiazolecarbonitrile.
Garozzo A; Stivala A; Tempera G; Castro A
Antiviral Res; 2010 Dec; 88(3):325-8. PubMed ID: 20955736
[TBL] [Abstract][Full Text] [Related]
6. Nectin-like interactions between poliovirus and its receptor trigger conformational changes associated with cell entry.
Strauss M; Filman DJ; Belnap DM; Cheng N; Noel RT; Hogle JM
J Virol; 2015 Apr; 89(8):4143-57. PubMed ID: 25631086
[TBL] [Abstract][Full Text] [Related]
7. A Single Amino Acid Substitution in Poliovirus Nonstructural Protein 2CATPase Causes Conditional Defects in Encapsidation and Uncoating.
Asare E; Mugavero J; Jiang P; Wimmer E; Paul AV
J Virol; 2016 Jul; 90(14):6174-6186. PubMed ID: 27076638
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs).
Schotte L; Thys B; Strauss M; Filman DJ; Rombaut B; Hogle JM
Antimicrob Agents Chemother; 2015 Aug; 59(8):4695-706. PubMed ID: 26014941
[TBL] [Abstract][Full Text] [Related]
9. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
[TBL] [Abstract][Full Text] [Related]
10. 6-(3,4-Dichlorophenoxy)-3-(ethylthio)-2-pyridincarbonitrile inhibits poliovirus uncoating.
González ME; Almela MJ; Yacout M; Carrasco L
Antimicrob Agents Chemother; 1990 Jun; 34(6):1259-61. PubMed ID: 2168147
[TBL] [Abstract][Full Text] [Related]
11. Conformational shift of a major poliovirus antigen confirmed by immuno-cryogenic electron microscopy.
Lin J; Cheng N; Hogle JM; Steven AC; Belnap DM
J Immunol; 2013 Jul; 191(2):884-91. PubMed ID: 23772035
[TBL] [Abstract][Full Text] [Related]
12. Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization.
Koromyslova AD; Hansman GS
PLoS Pathog; 2017 Nov; 13(11):e1006636. PubMed ID: 29095961
[TBL] [Abstract][Full Text] [Related]
13. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design.
Grant RA; Hiremath CN; Filman DJ; Syed R; Andries K; Hogle JM
Curr Biol; 1994 Sep; 4(9):784-97. PubMed ID: 7820548
[TBL] [Abstract][Full Text] [Related]
14. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds.
Rhoden E; Liu HM; Wang-Chern SW; Oberste MS
Antiviral Res; 2013 May; 98(2):186-91. PubMed ID: 23499651
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.
Salvati AL; De Dominicis A; Tait S; Canitano A; Lahm A; Fiore L
Antimicrob Agents Chemother; 2004 Jun; 48(6):2233-43. PubMed ID: 15155227
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of poliovirus uncoating by disoxaril (WIN 51711).
Zeichhardt H; Otto MJ; McKinlay MA; Willingmann P; Habermehl KO
Virology; 1987 Sep; 160(1):281-5. PubMed ID: 2820136
[TBL] [Abstract][Full Text] [Related]
17. Poliovirus infection without accumulation of eclipse particles.
Ofori-Anyinam O; Vrijsen R; Kronenberger P; Boeyé A
Antiviral Res; 1995 Jan; 26(1):27-35. PubMed ID: 7741519
[TBL] [Abstract][Full Text] [Related]
18. Early events in poliovirus infection: virus-receptor interactions.
Racaniello VR
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11378-81. PubMed ID: 8876143
[TBL] [Abstract][Full Text] [Related]
19. Antipoliovirus activity of isothiazole derivatives: mode of action of 5,5'-diphenyl-3,3'-diisothiazole disulfide (DID).
Garozzo A; Pinizzotto MR; Guerrera F; Tempera G; Castro A; Geremia E
Arch Virol; 1994; 135(1-2):1-11. PubMed ID: 8198435
[TBL] [Abstract][Full Text] [Related]
20. A human monoclonal antibody binds within the poliovirus receptor-binding site to neutralize all three serotypes.
Charnesky AJ; Faust JE; Lee H; Puligedda RD; Goetschius DJ; DiNunno NM; Thapa V; Bator CM; Cho SHJ; Wahid R; Mahmood K; Dessain S; Chumakov KM; Rosenfeld A; Hafenstein SL
Nat Commun; 2023 Oct; 14(1):6335. PubMed ID: 37816742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
